22210 Federal Register / Vol. 80, No. 76 / Tuesday, April 21, 2015 / Notices 

Control and Prevention, National Center 

for Health Statistics, 3311 Toledo Road, 

Auditorium B and C, Hyattsville, 

Maryland 20782, (301) 458–4125. 

Status: Open. 

Purpose: Section 1179 of the Health 

Insurance Portability and 

Accountability Act (HIPAA) creates an 

exemption from compliance with 

HIPAA and accompanying rules when a 

financial institution is ‘‘engaged in 

authorizing, processing, clearing, 

settling, billing, transferring or 

collecting payments.’’ The purpose of 

this meeting is to learn how banking 

and other financial service businesses 

are using personal health data as their 

services evolve in support of the health 

industry. 

The objectives of this hearing are as 

follows: 

Increase awareness of current and 

anticipated financial services involving 

personal health data, understand section 

1179 in light of these practices, and 

identify areas where outreach, 

education, technical assistance, or 

guidance may be useful. 

Contact Person For More Information: 

Debbie M. Jackson, Acting Executive 

Secretary, NCVHS, National Center for 

Health Statistics, Centers for Disease 

Control and Prevention, 3311 Toledo 

Road, Room 2339, Hyattsville, Maryland 

20782, telephone (301) 458–4614 or 

Maya Bernstein, ASPE/OSDP, Room 

436E, Department of Health and Human 

Services, 200 Independence Avenue 

SW., Washington, DC 20201, Phone: 

(202) 690–5896. Program information as 

well as summaries of meetings and a 

roster of committee members are 

available on the NCVHS home page of 

the HHS Web site: http://

www.ncvhs.hhs.gov/, where further 

information including an agenda will be 

posted when available. 

Should you require reasonable 

accommodation, please contact the CDC 

Office of Equal Employment 

Opportunity on 770–488–3204 as soon 

as possible. 

Dated: April 15, 2015. 

James Scanlon, 

Deputy Assistant Secretary for Planning and 

Evaluation, Science and Data Policy, Office 

of the Assistant Secretary for Planning and 

Evaluation . 

[FR Doc. 2015–09187 Filed 4–20–15; 8:45 am] 

BILLING CODE 4151–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Assessing an 

Online Process To Study the 

Prevalence of Drugged Driving in the 

U.S.: Development of the Drugged 

Driving Reporting System (NIDA) 

SUMMARY: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on November 24, 

2014, page 69864 and allowed 60 days 

for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The 

National Institute on Drug Abuse 

(NIDA), the National Institutes of 

Health, may not conduct or sponsor, 

and the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a currently valid 

OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact the NIDA Contract 

Officer’s Representative (COR) Harold 

Perl, Ph.D., Chief, Prevention Research 

Branch, Division of Epidemiology, 

Services & Prevention Research, NIDA, 

6001 Executive Blvd., Rockville, MD 

20852 or call this non-toll-free number 

(301) 443–6504 or email your request, 

including your address to: hperl@

nida.nih.gov. Formal requests for 

additional plans and instruments must 

be requested in writing. 

Proposed Collection: Assessing an 

Online Process to Study the Prevalence 

of Drugged Driving in the U.S: 

Development of the Drugged Driving 

Reporting System, 0925–New, National 

Institute on Drug Abuse (NIDA), 

National Institutes of Health (NIH). 

Need and Use of Information 

Collection: The study seeks to provide 

an improved understanding of the 

prevalence of drugged driving among 

adult drivers in the U.S and will assess 

the effectiveness of the online survey 

implementation process. The primary 

objectives of the study are to: (a) To 

provide comprehensive data on drugged 

driving; (b) determine if the Drugged 

Driving Survey Instrument (DDS) is an 

effective and accurate measure of 

drugged driving among licensed U.S. 

Drivers aged 18 and older. and, (c) to 

assess the effectiveness of the survey 

implementation process, including 

various levels of incentives for 

participation to determine the 

appropriate/optimal incentive amount 

needed to obtain the desired number of 

total survey respondents within the 

timeframe within which survey data 

will be collected. The findings will 

provide valuable information 

concerning various aspects of substance 

use and driving behavior, including: (1) 

Demographic information about drivers 

who do and do not drive while impaired 

by medication and/or drugs (e.g. age, zip 

code, type of driver’s license); (2) which 

drugs/medications are most likely to be 

used while driving; (3) drivers’ beliefs 

and attitudes toward drugged driving. 

OMB approval is requested for 2 

years. There are no costs to respondents 

other than their time. The total 

annualized estimated burden hours are 

750. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

Drugged Driving Survey .................................. Adults ................................. 3,750 1 12/60 750 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 76 / Tuesday, April 21, 2015 / Notices 22211 

Dated: April 14, 2015. 

Genevieve deAlmeida, 

Project Clearance Liaison, National Institute 

on Drug Abuse. 

[FR Doc. 2015–09089 Filed 4–20–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Child Health and the 

Environment Review Committee. 

Date: May 12–14, 2015. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crystal City Marriott at Reagan 

National Airport, 1999 Jefferson David 

Highway, Arlington, VA 22202. 

Contact Person: Linda K Bass, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research and 

Training, Nat’l Institute Environmental 

Health Sciences, P.O. Box 12233, MD EC–30, 

Research Triangle Park, NC 27709, (919) 541– 

1307. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Cell Differentiation Assays. 

Date: May 15, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Chapel Hill, One Europa 

Drive, Chapel Hill, NC 27517. 

Contact Person: Sally Eckert-Tilotta, Ph.D., 

Scientific Review Officer, Nat. Institute of 

Environmental Health Sciences, Office of 

Program Operations, Scientific Review 

Branch, P.O. Box 12233, Research Triangle 

Park, NC 27709, (919) 541–1446 eckertt1@

niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: April 15, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–09061 Filed 4–20–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 60-Day Comment 

Request; Prostate, Lung, Colorectal 

and Ovarian Cancer Screening Trial 

(PLCO) (NCI) 

SUMMARY: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute (NCI), 

National Institutes of Health (NIH), will 

publish periodic summaries of proposed 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 

Written comments and/or suggestions 

from the public and affected agencies 

are invited on one or more of the 

following points: (1) Whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

To Submit Comments and for Further 

Information: To obtain a copy of the 

data collection plans and instruments, 

submit comments in writing, or request 

more information on the proposed 

project, contact: Kelly Yu, Ph.D., 

Division of Cancer Prevention, 9609 

Medical Center Drive, Room 5E230, 

Rockville, MD 20850 or call non-tollfree number 240–276–7041 or Email 

your request, including your address to: 

yuke@mail.nih.gov. Formal requests for 

additional plans and instruments must 

be requested in writing. 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Proposed Collection: Prostate, Lung, 

Colorectal, and Ovarian Cancer 

Screening Trial (PLCO), 0925–0407, 

Extension, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: This is a request for a 

revision of the Prostate, Lung, Colorectal 

and Ovarian Cancer Screening Trial 

(PLCO). This trial was designed to 

determine if cancer screening for 

prostate, lung, colorectal, and ovarian 

cancer can reduce mortality from these 

cancers which caused an estimated 

253,320 deaths in the U.S. in 2014. The 

design is a two-armed randomized trial 

of men and women aged 55 to 74 at 

entry. OMB first approved this study in 

1993 and has approved it every 3 years 

since then. Recruitment was completed 

in 2001, baseline cancer screening was 

completed in 2006, and data collection 

continues on the current cohort of 

77,281 participants who are actively 

being followed. The additional followup will provide data that will clarify 

further the long term effects of the 

screening on cancer incidence and 

mortality for the four targeted cancers. 

Further, demographic and risk factor 

information may be used to analyze the 

differential effectiveness of cancer 

screening in high versus low risk 

individuals. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

26,320. 


tkelley on DSK3SPTVN1PROD with NOTICES